Drug Type Small molecule drug |
Synonyms Fosmetpantotenate (USAN) |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H31N2O9P |
InChIKeyHUWUHKIPYXWUPN-YVRVQSMLSA-N |
CAS Registry1858268-66-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10934 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | US | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | DE | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | IT | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | CZ | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | FR | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | PL | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | ES | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | CA | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | IND Application | NO | 17 Jul 2017 |
Phase 3 | 84 | ubdodjqmpm(kysdweratv) = qdzvxulfpn hfiosmcftg (afluupvxlx, 11.4) View more | Negative | 01 Jun 2021 | |||
Placebo | ubdodjqmpm(kysdweratv) = ykkdhoeter hfiosmcftg (afluupvxlx, 11.5) View more | ||||||
Phase 3 | 84 | (Fosmetpantotenate) | pdrnplkfzb(kiqarehehs) = xtugmqzdxq locipavnuv (saeeggitta, yqsscwyncy - jixmhcampk) View more | - | 29 Dec 2020 | ||
Placebo (Placebo) | pdrnplkfzb(kiqarehehs) = bvwmimyqdr locipavnuv (saeeggitta, stdskjitrn - ibwmyvflcf) View more |